ABCL — AbCellera Biologics Inc.

Summary of AbCellera's Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Approximately $8 million for Q1 2026, up from $4 million in Q1 2025, primarily from research fees.
• R&D Expenses: Approximately $47 million, an increase of $4 million year-over-year, reflecting investment in internal programs.
• SG&A Expenses: Approximately $12 million, down from $19 million in the prior year, attributed to the conclusion of intellectual property litigation and team restructuring.
• Net Loss: Roughly $43 million, compared to a loss of $46 million in Q1 2025, translating to a loss of $0.14 per share.
• Cash Position: Ended the quarter with about $530 million in cash and equivalents, plus $125 million in committed government funding, indicating strong liquidity for ongoing operations.

2. Strategic Updates and Business Highlights

• Pipeline Progress:
  • Lead program ABCL635 has advanced to Phase II testing, with top-line data expected in Q3 2026.
  • Interim Phase I data for ABCL635 shows favorable safety and pharmacokinetics, supporting its potential as a first-in-class treatment for vasomotor symptoms (VMS) associated with menopause.
  • ABCL575, another clinical program, is expected to report Phase I results in Q4 2026.
  • Plans to introduce at least one new development candidate by mid-2026, with additional programs (ABCL688 and ABCL386) anticipated to start clinical development by the end of 2027.

3. Forward Guidance and Outlook

• Upcoming Milestones:
  • Top-line data for ABCL635 in Q3 2026 is crucial for assessing its efficacy and safety.
  • The company remains on track for multiple catalysts over the next 24 months, including further clinical advancements and potential late-stage development for ABCL635.
• Market Potential: The total addressable market for non-hormonal VMS treatments is estimated at over $6 billion annually in the U.S., with significant upside potential.

4. Bad News, Challenges, or Points of Concern

• Net Loss: The ongoing net loss indicates continued investment in R&D without immediate profitability.
• Revenue Decline in Research Fees: As the company focuses on its internal pipeline, research fee revenue is expected to trend lower, which could impact overall revenue.
• Scientific Risks: While there is optimism around ABCL635's target engagement and potential efficacy, there remains uncertainty regarding its performance compared to existing small molecule treatments, which will be clarified in the upcoming Phase II results.

5. Notable Q&A Insights

• Testosterone Suppression and Efficacy: There is a strong belief that the observed testosterone suppression with ABCL635 could correlate with improved efficacy in treating VMS, but definitive results will come from the Phase II study.
• Dosing Strategy: The decision to use a 600 mg dose in Phase II is based on pharmacokinetic modeling, with expectations that it will maintain effective testosterone suppression.
• Expansion into Oncology: There is potential for ABCL635 to address VMS in patients undergoing cancer treatments, which could broaden its market applicability.
• Regulatory Engagement: Future discussions with regulators may determine the need for additional dose optimization before moving to Phase III trials.

Overall, AbCellera is positioned for significant developments in 2026, with a strong focus on advancing its pipeline while managing financial performance amid ongoing R&D investments.